COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
16 août 2023 08h58 HE
|
COMPASS Pathways
Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net proceeds...
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
03 août 2023 07h00 HE
|
COMPASS Pathways
LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program ongoing and on trackCPT® III code for in-person psychedelic therapy support accepted by the American Medical...
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
31 juil. 2023 08h32 HE
|
COMPASS Pathways
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
25 juil. 2023 04h00 HE
|
COMPASS Pathways
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
17 juil. 2023 04h00 HE
|
COMPASS Pathways
Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 ...
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
13 juil. 2023 04h00 HE
|
COMPASS Pathways
Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment.Authors...
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
06 juil. 2023 07h00 HE
|
COMPASS Pathways
New code will facilitate reimbursement for psychedelic therapy in the US, if approvedCOMPASS Pathways to hold webinar on new code on Tuesday, July 11, 8:00 am EDT (1:00 pm BST) LONDON, July 06, 2023...
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
05 juil. 2023 07h00 HE
|
COMPASS Pathways
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today...
COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences
16 juin 2023 07h00 HE
|
COMPASS Pathways
LONDON, June 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways' key patents upheld by the US Patent and Trademark Office
06 juin 2023 08h00 HE
|
COMPASS Pathways
PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent).In June...